Publicaciones en colaboración con investigadores/as de Queen Mary University of London (202)

2024

  1. Avoiding the use of long-term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut–Brain Interaction

    Neurogastroenterology and Motility, Vol. 36, Núm. 9

  2. Avoiding the use of long-term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut–Brain Interaction

    Clinical Nutrition, Vol. 43, Núm. 9, pp. 2279-2282

  3. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology, Vol. 86, Núm. 1, pp. 4-9

  4. Correction to: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  5. Development and validation of prediction models for fetal growth restriction and birthweight: an individual participant data meta-analysis

    Health technology assessment (Winchester, England), Vol. 28, Núm. 47, pp. 1-119

  6. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

    European Urology Focus

  7. Highest oxygen consumption prediction: introducing variable theoretical proportional factors for different sports

    European Journal of Applied Physiology

  8. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals

    Neurology and Therapy, Vol. 13, Núm. 4, pp. 1015-1038

  9. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, Núm. 3, pp. 219-244

  10. Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. A systematic review and meta-analysis of the clinimetric properties of the core outcome measurement instruments for clinical effectiveness trials of nutritional and metabolic interventions in critical illness (CONCISE)

    Critical Care, Vol. 27, Núm. 1

  4. Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

    Clinical Cancer Research, Vol. 29, Núm. 21

  5. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  6. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  7. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  8. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Annals of Oncology

  9. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299

  10. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176